Table 3.
Genotyping results in cancer case and noncancer control subjects.
| Case (N = 197) |
Control (N = 416) |
||||
|---|---|---|---|---|---|
| Genotype | No. | % | No. | % | p value † |
| CYP1A1 | .73 | ||||
| Not done | 7 | (3.4) | 6 | (1.4) | |
| *1/*1 | 162 | 85.3 | 345 | 84.1 | |
| non-*1/*1 | 28 | 14.7 | 65 | 15.9 | |
| CYP2E1 | .36 | ||||
| Not done | 7 | (3.4) | 13 | (3.1) | |
| G/G C/C | 176 | 92.6 | 364 | 90.3 | |
| non-G/C C/C | 14 | 7.4 | 39 | 9.7 | |
| GSTM1 | .5 | ||||
| Not done | 1 | (0.5) | 2 | (0.5) | |
| Null | 126 | 64.3 | 276 | 66.7 | |
| non-null | 70 | 35.7 | 138 | 33.3 | |
| GSTT1 | .22 | ||||
| Not done | 2 | (1.0) | 2 | (0.5) | |
| Null | 67 | 34.4 | 122 | 29.5 | |
| non-null | 128 | 65.6 | 292 | 70.5 | |
| mEH activity | .95 | ||||
| Not done | 1 | (0.5) | 2 | (0.5) | |
| rapid | 34 | 17.3 | 70 | 16.9 | |
| normal | 86 | 43.9 | 192 | 46.4 | |
| slow | 62 | 31.6 | 126 | 30.4 | |
| very slow | 14 | 7.1 | 26 | 6.3 | |
| MPOG463A | .99 | ||||
| Not done | 0 | (0.0) | 2 | (0.5) | |
| G/G | 123 | 62.4 | 259 | 62.6 | |
| G/A | 64 | 32.5 | 133 | 32.1 | |
| A/A | 10 | 5.1 | 22 | 5.3 | |
| GSTP1 | .74 | ||||
| Not done | 1 | (0.5) | 2 | (0.5) | |
| A/A, A/B, A/D | 155 | 79.1 | 336 | 81.2 | |
| B/B, B/C, C/C, C/D, D/D | 24 | 12.2 | 42 | 10.1 | |
| A/C or B/D | 17 | 8.7 | 36 | 8.7 | |
| NAT2 | .03 | ||||
| Not done | 15 | (7.4) | 17 | (4.1) | |
| Fast | 98 | 53.8 | 175 | 43.9 | |
| Slow | 84 | 46.2 | 224 | 56.1 | |
†
Chi-square, genotype distribution in case versus control subjects, excluding subjects with missing genotype.